

NCIC CLINICAL TRIALS GROUP - GI DISEASE SITE COMMITTEE

COLON DISEASE ORIENTED GROUP

AGENDA

OPEN SESSION

Venue: Rossetti Room, Delta Chelsea Hotel, Toronto

Date: Saturday, April 28th, 2012

Time: 13:30 to 15:30 hrs

Dr. Derek Jonker & Dr. Sharlene Gill

- 13:30 WELCOME AND INTRODUCTION DR. D. JONKER / DR. S. GILL
- 13:30 - 13:45 CLOSED TRIALS – UPDATED ANALYSIS
- CO.20:** A PHASE III RANDOMIZED STUDY OF BRIVANIB ALANINATE (BMS-582664) IN COMBINATION WITH CETUXIMAB (ERBITUX®) VERSUS PLACEBO IN COMBINATION WITH CETUXIMAB (ERBITUX®) IN PATIENTS PREVIOUSLY TREATED WITH COMBINATION CHEMOTHERAPY FOR METASTATIC COLORECTAL CARCINOMA DR. L. SIU
- 13:45 - 15:15 APPROVED / ACTIVE TRIALS FOR DISCUSSION
- IND 210:** A RANDOMIZED PHASE II STUDY OF FOLFOX/BEVACIZUMAB +/- REOLYSIN IN METASTATIC COLORECTAL CANCER DR. P. TANG
- CO.23:** A PHASE II/III RANDOMIZED STUDY OF BBI608 AND BEST SUPPORTIVE CARE VERSUS PLACEBO AND BEST SUPPORTIVE CARE IN PATIENTS WITH PRETREATED METASTATIC COLORECTAL CARCINOMA DR. D. JONKER
- CO.21:** A PHASE III STUDY OF THE IMPACT OF A PHYSICAL ACTIVITY PROGRAM ON DISEASE-FREE SURVIVAL IN PATIENTS WITH EARLY STAGE COLON CANCER: A RANDOMIZED CONTROLLED TRIAL (CHALLENGE) DR. K. COURNEYA
- CRC.6 (CALGB 80702):** A PHASE III TRIAL OF 6 VERSUS 12 TREATMENTS OF ADJUVANT FOLFOX PLUS CELECOXIB OR PLACEBO FOR PATIENTS WITH RESECTED STAGE III COLON CANCER DR. F. COUTURE
- IND 208:** A PHASE I TRIAL OF PANITUMUMAB + BKM120, AN ORAL PI3K INHIBITOR, IN COLORECTAL CANCER. DR. R. GOODWIN / D. JONKER
- 15:15 – 15:30 INTERGROUP TASK FORCE UPDATE DR. D. JONKER / S. GILL
- 15:30 CLOSING REMARKS